Introduction
Human papillomaviruses (HPVs) are small DNA viruses that infect various human epithelial tissues. HPVs are classified as either high-or low-risk on the basis of clinical association. The low-risk HPV types, such as 6 and 11, are associated primarily with benign lesions that rarely develop to cancer. The high-risk HPV types, such as HPV16 and 18, are associated with lesions that can progress to neoplasia and ultimately cancer (see, zur Hausen, 1999; Munger and Howley, 2002 , for reviews). HPV16 and 18 are found in more than 95% of human cervical cancers and 25% of human head and neck cancers. Molecular studies indicate that two viral oncogene products of high-risk HPVs, E6 and E7, are essential for the tumorigenecity of HPV infection. Both E6 and E7 modulate apoptosis that is important for HPV-infected cells to evade immunological response during progression to cancer (see, Mantovani and Banks, 2001; Finzer et al., 2002 , for reviews). E6 expression rapidly promotes p53 ubiquitination and degradation through association with ubiquitin ligase E6AP, thereby abolishing p53-mediated apoptosis and other functions such as cell cycle regulation. E6 also mediates degradation of several other proapoptotic proteins such as Bak and c-Myc (Gross-Mesilaty et al., 1998; Thomas and Banks, 1998) . In addition, E6 and E7 can modulate apoptosis via alteration of gene expression. For example, transcription regulator nuclear factor-kB (NF-kB) expression is upregulated and its activity is increased as a result of the expression of HPV16 E6 and E7 in human keratinocyte (Nees et al., 2001) . Increased NF-kB can activate the transcription of inhibitor of apoptosis (IAP) family proteins XIAP, cellular inhibitor of apoptosis protein 1 (c-IAP1), and c-IAP2 to antagonize tumor necrosis factor-a (TNF-a)-mediated apoptosis (Rothe et al., 1995; Uren et al., 1996; Stehlik et al., 1998) . However, the roles of these IAPs in E6-and E7-mediated inhibition of apoptosis have not been defined.
The human IAP family proteins, which include c-IAP1, c-IAP2, NAIP, Survivin, XIAP, Bruce, ILP-2 and Livin, are potent inhibitors of apoptosis and potentially involved in human cancer formation (see, Salvesen and Duckett, 2002; Nachmias et al., 2004 , for reviews). These proteins are highly conserved from fly to human. Cellular inhibitor of apoptosis protein 2 (c-IAP2) was initially identified as a molecule that is recruited to TNF receptor via its association with TNF receptorassociated factor 1 and 2 (TRAF1 and TRAF2) (Rothe et al., 1995) . Two major mechanisms are involved in the c-IAP2 inhibition of apoptosis. First, c-IAP2 directly binds and inhibits caspase-3, -7 and -9, but not caspase-8 (Roy et al., 1997; Deveraux et al., 1998) . Second, c-IAP2 possesses C-terminal RING domain that contains intrinsic ubiquitin ligase activity. The RING domain of c-IAP2 transfers polyubiquitin chains to proapoptotic proteins, leading to rapid degradation of these ubiquitinized proteins by proteasome (see, Zhang et al., 2004 , for a review). Recent studies indicated that the inhibition of TNF-a-induced apoptosis might result from the c-IAP2-and c-IAP1-mediated degradation of TRAF2 and receptor interacting protein (RIP), both of which are necessary for the transmission of TNF-a-mediated apoptosis signaling Park et al., 2004) . Other proapoptotic proteins such as the second mitochondria-derived activator of caspases (Smac)/DIABLO, caspase-3 and -7, are also found to be degraded by c-IAP2 (Huang et al., 2000; Hu and Yang, 2004) .
Given that c-IAP2 plays a significant role in apoptosis, it is not surprising that its expression is tightly regulated. The c-IAP2 promoter contains multiple transcription factor binding sites including AP-1, NF-kB and glucocorticoid response element (GRE) (Chu et al., 1997; Hong et al., 2000) . Functional studies demonstrated that there were three NF-kB binding sites in c-IAP2 promoter and the first and third sites are required for antagonizing TNF-a, CD40-and LMP1-mediated apoptosis (Hong et al., 2000) . In addition to NF-kB, dexamethasone was reported to stimulate c-IAP2 gene expression through the GRE site (Webster et al., 2002) . A recent report showed that two CREB binding domains (CRE) in the c-IAP2 promoter were required for cAMP-induced c-IAP2 transcriptional activation in human intestinal epithelial cells (Nishihara et al., 2004) . In addition, the stability of c-IAP2 protein is also highly regulated. c-IAP2 protein is selectively degraded by Smac/DIABLO that is necessary for caspase-8 activation (Yang and Du, 2004) . Also, the mammalian IAPs binding proteins Omi/HtrA2 can directly cleave c-IAP2 protein and result in the activation of caspase-3 (Yang et al., 2003) . The multiple regulations of c-IAP2 levels may be required for cells to rapidly respond to different apoptotic stimuli.
The apoptosis inhibitory function of c-IAP2 raises the possibility that c-IAP2 contributes to carcinogenesis. Indeed, aberrant c-IAP2 expression has been found in a variety of human cancers (see, Nachmias et al., 2004, for review) . c-IAP2 was shown to be upregulated in nonsmall-cell lung cancer (NSCLC) cells (Ferreira et al., 2001) . t(11;18)(q21;q21) translocation of c-IAP2 in mucosa-associated lymphoid tissue (MALT) lymphoma results in the generation of c-IAP2-MALT1 fusion protein that confers resistance to apoptosis. The fusion protein was solely responsible for the malignant transformation (Dierlamm et al., 1999; Hosokawa et al., 2004) . We previously reported that the mRNA level of c-IAP2 was dramatically increased in HPV16 E6/E7-immortalized human oral keratinocytes HO-K16E6E7 (Nishitani et al., 2002) . We hypothesized that the increase of c-IAP2 might enhance the resistance to apoptosis and contribute to cellular transformation caused by HPV16 E6 and E7. In this report, we found that HPV16 E6/E7 upregulates c-IAP2 transcription that was dependent on NF-kB activity. In addition, continuous expression of c-IAP2 was required for the sustained growth of immortalized HOK16E6E7 and some high-risk HPV-associated cancer cells.
Results

c-IAP2 expression decreased in fully differentiated normal human oral keratinocytes (NHOK) but increased in the immortalized HOK16E6E7
We previously showed by screening a high-density oligonucleotide gene chip array (Nishitani et al., 2002) that the c-IAP2 gene was upregulated in HOK16E6E7 compared to NHOK. The HOK16E6E7 cells were established by infection with a recombinant retrovirus containing the HPV16 E6 and E7 oncogenes (Miller and Rosman, 1989) . Unlike the immortalized HOK16E6E7, which have an unlimited lifespan, primary NHOK have a finite lifespan with approximately 20 population doublings (PD) before they terminally differentiate, senesce and eventually die by apoptosis (Min et al., 1999; Nishitani et al., 2002) . To assess the c-IAP2 expression in NHOK and HOK16E6E7, total RNA and proteins were collected from NHOK at different passages and from immortalized HOK16E6E7 (passage >60). Northern blot analysis indicated that c-IAP2 mRNA gradually decreased in NHOK cells at late passages and immortalized HOK16E6E7 showed higher c-IAP2 level (Figure 1a ). c-IAP2 mRNA in HO-K16E6E7 was 7.8-fold higher than NHOK at passage 5 (approximately 18 PD). Reverse transcriptase-polymerase chain reaction (RT-PCR) showed similar results ( Figure 1b) . The presence of HPV16 E6 and E7 in HOK16E6E7 was confirmed by RT-PCR (Figure 1c ). Western blot analysis demonstrated a parallel alteration of c-IAP2 protein (Figure 1d ). The decrease of c-IAP2 expression in NHOK at late passages suggested that c-IAP2 decrease in NHOK might associate with cell differentiation. Involucrin, the terminal differentiation marker of keratinocytes, was measured to evaluate the differentiation of NHOK. The involucrin level of NHOK increased in passages 3 and 5, but was significantly decreased in the immortalized HO-K16E6E7 in which the differentiation was inhibited (Figure 1d ). Thus, c-IAP2 expression decreased to a low level in differentiated NHOK, but remained at a high level in HPV16E6E7-immortalized HOK16E6E7.
Transcriptional activation of the c-IAP2 promoter by E6 and E7 proteins
To characterize the transcriptional regulation of c-IAP2 by HPV E6 and E7, we conducted a c-IAP2 promotercontrolled luciferase reporter assay. E6 and/or E7 of low-risk HPV6, high-risk HPV16 or 18 were cotransfected with a fully active c-IAP2 promoter-controlled c-IAP2 upregulation by HPV E6 and E7 H Yuan et al luciferase reporter construct (À900 LUC; Hong et al., 2000) . The ectopically expressed E6/E7 were examined by Western blot using anti-HA antibody (Figure 2c ). The luciferase assay (Figure 2a ) indicated that HPV16 E6 and E7 activated luciferase expression by seven-and one-fold above the LacZ control, respectively. Coexpression of HPV16 E6 and E7 further increased the luciferase expression to 7.8-fold, demonstrating an additive effect. Similar results were observed in cells overexpressing HPV18 E6/E7 oncoproteins ( Figure 2a ). On the contrary, expression of HPV6 E6/E7 proteins, which do not possess oncogenic property, did not significantly activate the c-IAP2 promoter. Thus, the induction of c-IAP2 transcription by HPV16 or 18 E6/E7 proteins appeared to be associated with their oncogenic potential.
The above results showed that HPV16 and 18 E6, not E7, played a major role in the activation of c-IAP2 transcription (Figure 2a ). To further characterize the E6-mediated c-IAP2 upregulation, we examined the effect of two HPV16 E6 mutants 8S9A10T and D118-122, which are defective in the induction of p53 degradation and telomerase activation (Foster et al., 1994; Duffy et al., 2003) . Both E6 mutants were not able to activate the c-IAP2 promoter (Figure 2b ). These results suggested that HPV16 E6-induced upregulation of c-IAP2 might be associated with p53 degradation and telomerase activation. 
Increased transcription of c-IAP2 by HPV16 E6 required NF-kB
Transcription of c-IAP2 is controlled by multiple regulatory elements in its promoter region. To identify the transcription factor that mediates HPV16 E6/E7 upregulation of c-IAP2 expression, we conducted a deletion and multiple mutation analysis in the 900 bp c-IAP2 promoter (À900 LUC). The luciferase reporter assay demonstrated that 247 bp upstream of the promoter were sufficient for HPV16 E6/E7 induced c-IAP2 transcriptional activation (Figure 3a ). This 247 bp region contains three NF-kB binding sites and one AP-1 site. Mutation of AP-1 (À247(mAP1)) did not affect E6/ E7-induced c-IAP2 promoter activation, suggesting that E6/E7 activation of c-IAP2 did not involve the AP-1 transcription factor. However, mutation at either one of the three NF-kB sites significantly reduced the activation of c-IAP2 promoter in response to E6/E7 expression. A single mutation at the third NF-kB site (À247(mkB3)) reduced the promoter activation by approximately five-fold (Figure 3a) . Similar results were also observed in the presence of either E6 or E7 alone. Thus, NF-kB was necessary for HPV16 E6/E7-induced c-IAP2 transcriptional upregulation.
To further confirm the role of NF-kB in HPV16 E6/E7-mediated c-IAP2 transcription, we utilized an NF-kB-defective HEp2 cell line, HEp2-IkB (S32AS36A) . This cell line stably expresses the NF-kB super-repressor IkB (S32AS36A) mutant, which constitutively inhibits NFkB activity (Jewett et al., 2003) . The activation of c-IAP2 transcription by TNF-a, which requires functional NF-kB, was approximately two-fold lower in HEp2-IkB (S32AS36A) cells than that in the control cells HEp2-pRcCMV, which has been stably transfected with the empty vector. Likewise, HPV16 E6/E7 expressioninduced activation of c-IAP2 promoter was significantly inhibited in HEp2-IkB (S32AS36A) cells, indicating that NF-kB played an important role in the upregulation of c-IAP2 by HPV16 E6/E7 (Figure 3b ).
Ectopic expression of c-IAP2 protected NHOK from TNF-a/cycloheximide (CHX) induced apoptosis
To evaluate the effect of upregulation of c-IAP2 in HOK16E6E7, we ectopically expressed HA-tagged c-IAP2 in NHOK using a lentiviral vector and examined the antiapoptosis effect. NHOK (passage 1) were infected with an equal amount of HR 0 c-IAP2 virus or control virus HR 0 GFP, which expresses green fluorescence protein. The virus was titrated to ensure that more than 95% of the cells expressed the exogenous gene by microscopically evaluating GFP expression in HR 0 GFP virus-infected cells. To induce apoptosis, the cells were treated for 18 h with TNF-a (30 ng/ml) alone or in combination with sublethal doses of the protein synthesis inhibitor CHX (30 mg/ml) as sensitizer ( Thompson et al., 2001) . Ectopic c-IAP2 expression was confirmed by Western blot using both anti-HA and antic-IAP2 antibodies (Figure 4a ). CHX or TNF-a single treatment did not cause significant cell death and only a basal level of caspase-3 activities was detected. Overexpression of c-IAP2 in NHOK decreased the caspase-3 activity by 50% in response to TNF-a/CHX treatment, demonstrating significant resistance to TNF-a/CHXinduced apoptosis (Figure 4b ). Similar results were found by in situ terminal deoxynucleotidyl transferasemediated dUTP nick-end labeling (TUNEL) analysis, which measures the breakage of DNA as a result of apoptosis (Figure 4c ). The percentage of TUNELpositive cells in HR 0 GFP-infected NHOK was approximately 38% compared with 21% in HR 0 c-IAP2-infected NHOK. These results indicated that high level of c-IAP2 expression could significantly alleviate TNF-a/CHX induced apoptosis in NHOK.
Depletion of c-IAP2 caused apoptosis in immortalized HOK16E6E7
Based on the above results, we hypothesized that the upregulation of c-IAP2 by HPV16 E6/E7 directly contributed to apoptosis resistance in the immortalized HOK16E6E7. To test the hypothesis, we designed an anti-c-IAP2 small interfering RNA (si c-IAP2) in a lentiviral vector to silence the endogenous c-IAP2 expression. HOK16E6E7 cells were infected with an equivalent amount of si c-IAP2 virus or control si Luc virus expressing siRNA against firefly luciferase . Cells were collected at 72 h post infection and Western blot analysis was conducted to examine the depletion of endogenous c-IAP2 in these cells. Densitometric quantification indicated that si c-IAP2 decreased the c-IAP2 expression by 86% in HOK16E6E7 (Figure 5a ). Caspase-3 activity assay showed that depletion of c-IAP2 in HOK16E6E7 increased the caspase-3 activity more than three-fold, indicating a higher level of apoptosis (Figure 5b) . In situ TUNEL staining demonstrated that 19% of the si IAP2-expressing cells were positive, compared to about 8% in the si Luc virus-infected cells (Figure 5c ). Thus, depletion of c-IAP2 directly led the immortalized HOK16E6E7 to apoptosis.
Depletion of c-IAP2 in HPV18-positive HeLa cervical carcinoma cells led to cell death HPV16 or 18 E6/E7-induced upregulation of c-IAP2 may be necessary for the resistance to apoptosis found in HPV-associated cancers. To test the hypothesis, we first examined the expression of c-IAP2 in several HPV16-and 18 positive cancer cells by RT-PCR. The data indicated that the c-IAP2 transcript levels were significantly higher in HPV16-positive cancer cell lines including HOK16B-BaP-T-, SiHa-, CaSki-, and HPV18-positive HeLa cells. The c-IAP2 expression level was relatively low in spontaneously immortalized HaCaT cells and HPV-negative SCC4 oral cancer cells (Figure 6a ). The E6/E7 expressions in these cell lines were confirmed by RT-PCR (data not shown). The results suggested that the increased c-IAP2 levels might be linked to HPV16/18-associated cancers. To examine whether c-IAP2 is involved in apoptosis resistance of HPV-positive cancer cells, we depleted c-IAP2 in HeLa cells (Figure 6b ). Like HOK16E6E7, HeLa cells were found to be sensitive to c-IAP2 depletion. Caspase-3 activity in si c-IAP2 virus-infected cells was 2.7-fold higher than that in si Luc virus-infected cells (Figure 6c ). The in situ TUNEL assay demonstrated a similar result (Figure 6d) . Thus, c-IAP2 expression in HeLa cells may be necessary for sustained cell growth.
Discussion
Our previous studies have shown that c-IAP2 transcription is increased in the immortalized HOK16E6E7 cells. It is therefore important to unravel the mechanism and the role of c-IAP2 upregulation by E6/E7 in human keratinocytes, the natural host of HPV infection. In this report, we identified that NF-kB-mediated HPV16 E6/ E7 induced upregulation of c-IAP2 gene expression, which was associated with the transformation functions of E6/E7. The increased c-IAP2 level appeared to induce resistance to TNF-a-mediated apoptosis. Importantly, depletion of c-IAP2 directly activated caspase-3 and led to apoptosis in the immortalized HOK16E6E7 and HeLa cells. These results indicate that sustained proliferation of HOK16E6E7 and certain HPVassociated carcinoma cells require high-level c-IAP2 expression.
In this study, we revealed that HPV16 E6/E7 induced c-IAP2 increase was NF-kB dependent. NF-kB is a transcription factor that controls immune responses, cellular proliferation and apoptosis. Constitutive activation of NF-kB has been found in numerous tumors including breast cancer, melanoma and squamous cell carcinoma (see, Karin et al., 2002 , for review). Nees et al. (2001) showed that HPV16 E6 increased expression of NF-kB subunits p50 and p65, and enhanced their binding to NF-kB DNA consensus binding sites. Moreover, E7 coexpression with E6 further enhanced NF-kB binding to the consensus sequence (Nees et al., 2001) . Our results showing that the activation of c-IAP2 transcription by E6/E7 is NF-kB dependent are in accordance with their observations. Like E6/E7 induced activation of NF-kB, E6 played a major role in the activation of c-IAP2 expression, and E7 coexpression with E6 further enhanced c-IAP2 expression. In addition, the activation of c-IAP2 transcription appeared to be associated with the transformation functions of highrisk E6 and E7 since low-risk HPV6 E6/E7 did not activate the c-IAP2 promoter. Also, HPV16 E6 mutants D118-122 (Foster et al., 1994) , which is defective in telomerase activation (Duffy et al., 2003) , failed to activate c-IAP2 expression. It has been shown that telomerase gene promoter contains two putative NF-kBbinding motifs (Yin et al., 2000) . Further investigation indicates that NF-kB is necessary for human Tlymphotropic virus type 1 (HTLV-1) oncoprotein Tax induced telomerase expression during transmission of HTLV-1 to primary T cells (Sinha-Datta et al., 2004) . In addition, NF-kB is reported to mediate estrogeninduced telomerase expression in MCF-7 human breast cancer cells (Kawagoe et al., 2003) . These reports suggest that both c-IAP2 and telomerase promoters might be controlled by NF-kB. Another E6 mutant 8S9A10T that cannot promote p53 degradation (Foster et al., 1994) failed to activate c-IAP2 transcription. The results suggest that p53 degradation might be necessary for E6-induced and NF-kB-mediated c-IAP2 expression. This observation is consistent with the previous report showing that p53 degradation mutant E6 F2 V is defective for NF-kB activation (Nees et al., 2001) . Further investigation of the mechanism by which E6 activates NF-kB may provide insight to understand the association of these different functions of E6. HPV16 E6/E7-induced activation of c-IAP2 transcription was similar to cytokine TNF-a-induced c-IAP2 activation, based on the observations that both TNF-a and HPV16 E6/E7 require the first and the third NF-kB sites in the c-IAP2 promoter (Hong et al., 2000) and the induction of c-IAP2 expression was significantly reduced in the NF-kB-deficient cell line. However, HPV16 E6/ E7-induced c-IAP2 transcription may not be mediated by TNF-a because HPV infection or E6 and E7 expression have been shown to reduce TNF-a expression in keratinocytes (Mota et al., 1999; Havard et al., 2002) . Also, HPV16 E6 and E7 were reported to attenuate TNF-a-mediated NF-kB activation (Spitkovsky et al., 2002) . TNF-a activates NF-kB through degradation of its inhibitor IkB, which allows NF-kB to translocate to the nucleus. However, HPV16 E6/E7 also increase the transcription of NF-kB subunits in addition to enhancing NF-kB nuclear translocation. To better understand the high-risk HPV E6/E7-induced resistance of apoptosis, it is necessary to clarify the molecular pathways that mediate E6/E7-induced activation of NF-kB.
Both E6 and E7 of high-risk HPV interfere with apoptosis. HPV16 and 18 E6 proteins promote degradation of several proapoptotic proteins such as p53, Bak and c-Myc (see, Mantovani and Banks, 2001; Finzer et al., 2002, for reviews) . A recent report showed that HPV16 E6 directly binds to TNF R1 receptor and protects cells from Fas-triggered apoptosis (Filippova et al., 2002) . The role of high-risk HPV E7 in apoptosis is more controversial and the mechanism is not well defined. On the one hand, E7-immortalized human fibroblasts are resistant against TNF-a/CHX-mediated cell death (Thompson et al., 2001 ) and suppression of E7 expression in cervical carcinoma cells by RNA interference causes apoptosis (Jiang and Milner, 2002) . On the other hand, E7 expression in keratinocyte sensitizes cells to TNF-a-mediated apoptosis (Stoppler et al., 1998) and predisposes human fibroblast to serum starvation-mediated apoptosis (Jones et al., 1997) . The inconsistency appears to result from different cell systems and apoptosis stimuli. Here, we clarified a new pathway showing that E6 and E7 might collaborate to inhibit apoptosis by transcriptional activation of c-IAP2. Increased c-IAP2 can not only directly inhibit caspase-3, -7 and -9 but also promote degradation of other proapoptotic molecules such as Smac/DIABLO (Hu and Yang, 2004) . Therefore, increase of c-IAP2 may target molecules at different levels of apoptosis signaling pathway. Since c-IAP2 can directly inhibit caspase-3, the distal executioner of apoptosis, the increased level of c-IAP2 maybe the last step to prevent apoptosis in HPV infected cells. The upregulation of c-IAP2 may collaborate with other inhibitory mechanisms, such as p53 degradation, to antagonize different apoptosis stimuli in vivo. We did notice that c-IAP2 overexpression could not completely inhibit caspase-3 activity and apoptosis induced by TNF-a/CHX. One possibility is that c-IAP2 is not the strongest inhibitor of caspase-3. In vitro caspase-3 activity assay demonstrated that the ability of c-IAP2 to inhibit caspase-3 was 50-fold weaker than that of XIAP (Salvesen and Duckett, 2002) . Furthermore, TNF-a/CHX strongly activates mitochondria apoptotic pathway that releases proapoptotic protein Smac/DIABLO into the cytoplasm. Cytoplasmic Smac/DIABLO can induce rapid degradation of c-IAP2 and diminish c-IAP2 apoptosis inhibitory ability (Yang and Du, 2004) . Nevertheless, the incomplete relief of apoptosis is sufficient to demonstrate that increased c-IAP2 expression significantly reduces apoptosis.
Evasion of apoptosis is one of the hallmarks of cancer cells (Hanahan and Weinberg, 2000) . The oncogenic property of c-IAP2 has been revealed in a chromosome translocation (t( 11;18)(q21;q21)) that results in the generation of c-IAP2-MALT1 fusion protein, which inhibits apoptosis and leads to malignant transformation (Dierlamm et al., 1999; Hosokawa et al., 2004) . We showed in this report that c-IAP2 expression decreased in differentiated NHOK but aberrantly increased in the immortalized HOK16E6E7. In addition, high level of c-IAP2 appeared to be necessary for the proliferation of immortalized HOK16E6E7. Depletion of c-IAP2 led to cell death, suggesting that HPV16-induced c-IAP2 expression is necessary to maintain immortalization. We also demonstrated that c-IAP2 levels in the four tested HPV16-or 18-positive cancer cell lines were significantly higher than that in HPV-negative SCC4 cancer cells and spontaneous immortalized HaCaT cells, indicating a correlation between HPV16-and 18-positive cancers and c-IAP2 overexpression. The high level of expression of c-IAP2 seems to be necessary for cancer cell survival because depletion of c-IAP2 directly led HeLa cells to apoptosis. These results demonstrate that upregulation of c-IAP2 expression plays an important role in HPV-associated cancers.
Materials and methods
Cell culture
Primary NHOKs were isolated from gingiva and cultured in serum-free KGM-2 medium Bulletkit (Cambrex, San Diego, CA, USA) as described (Nishitani et al., 2002) . Immortalized HOK16E6E7 cells were cultured in KGM-2 medium with 200 ng/ml G418. SCC4 were grown in F12/DMEM and 10% FBS. Other cells including NIH 3T3, 293 T, HeLa, Caski, SiHa, HEp2, HaCaT and HOK16B-BaP-T were cultured in 10% FBS-DMEM. HOK16B-BaP-T cells were further supplemented with 400 mg/ml hydrocortisone. HEp2 cell lines stably transfected with NF-kB super-repressor IkB (S32AS36A) or empty vector (pRcCMV) were cultured in c-IAP2 upregulation by HPV E6 and E7 H Yuan et al 10% FBS-DMEM supplemented with 800 mg/ml G418. The cells were maintained in 371C incubator with 5% CO 2 and split twice per week.
Plasmid construction
pSG5 HPV18E6 and E7 with a hemagglutinin (HA) tag at the N-terminal were obtained from SM Huang (Tri-Service General Hospital, Taipei, Taiwan) . HPV6 E6, HPV6 E7, HPV16 E6 and E7 cDNAs were generated by PCR from HPV6 and HPV16 genomic DNA, and HVP16 E6 mutants 8S9A10T and D118-122 were amplified by PCR from an LXSN-based retroviral vector kindly provided by DA Galloway (Fred Hutchinson Cancer Research Center, Seattle, WA, USA). All the PCR products were inserted into HA-tagged pSG5 vector between EcoRI and BamHI sites. c-IAP2 promoter-controlled luciferase reporter construct À900 Luc and the À247 Luc and all NF-kB mutants were generously provided by TH Lee (Yonsei University, Seoul, South Korea). The AP-1 site mutation in 247 bp promoter region was generated by PCR using site mutagenesis kit (Stratagene, La Jolla, CA, USA). The primers were as follows: sense, 5
0 -GAGTCATGCTTT TAGATAATGGAAATCCCCGAG-3 0 ; antisense, 5 0 -CTCG GGGATTTCCATTATCTAAAAGCATGACTC-3 0 . The mutated nucleotides are underlined. pHR 0 c-IAP2, the lentiviral vector bearing c-IAP2 cDNA, was generated by cloning the full-length cDNA with a C-terminal HA tag into a lentiviral vector derived from pHR 0 CMV-EGFP (Yuan et al., 2003) . All the sequences of constructs were verified by DNA sequencing (Laragen Inc., Los Angeles, CA, USA).
RT-PCR
Total RNA was isolated using RNeasy Kit (Qiagen, Chatsworth, CA, USA). RT-PCR was conducted using Super Script One
Step RT-PCR kit as instructed by the manufacturer (Invitrogen, Carlsbad, CA, USA). The oligonucleotide primers were as follows: c-IAP2 sense, 5 0 -CTACGTATTCCACTTTTC CT-3 0 ; c-IAP2 antisense, 5 0 -AAGTACTCACACCTTGGAAA CCA-3 0 ; 16E6 sense, 5 0 -ATGCACCAAAAGAGAACTGCA-3 0 ; 16E6 antisense, 5 0 -TTACAGCTGGGTTTCTCTACG-3 0 ; 16E7 sense, 5 0 -TCATGCATGGAGATACACCTACAT-3 0 ; 16E7 antisense: 5 0 -TTATGGTTTCTGAGAACAGATGG-3 0 ; GAPDH was measured as RNA loading control. Densitometric units per square micrometer area were determined using an image analysis software (NIH Image 1.61).
Northern blot analysis
Northern blot analysis was performed as described (Yuan et al., 2003) . Briefly, total RNA (10 mg) isolated using an RNeasy kit was resolved by agarose/formaldehyde gel electrophoresis. Samples were then transferred to nylon membrane and hybridized with 32 P-labeled human c-IAP2 (nt 1002-1815) and b-actin cDNAs in ExpressHyb hybridization solution (Clontech, Palo Alto, CA, USA) according to the manufacturer's instructions. The results were visualized and quantified using a Phosphor Imager (Molecular Dynamics, Sunnyvale, CA, USA). The numbers represent the relative density of c-IAP2 mRNA after normalization against -actin.
Western blot analysis
Cells were lysed with lysis buffer containing 1% NP-40, 137 mM sodium chloride, 20 mM Tris, pH 7.4, 1 mM dithiothreitol, 10 mM sodium fluoride, 1 mM pyrophosphate, 2 mM sodium vanadate, and protease inhibitor cocktail (SigmaAldrich Corp., St Louis, MO, USA). Protein concentrations were measured by Bradford assay (Bio-Rad, Hercules, CA, USA). Cell lysates were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted to nitrocellulose membrane. Blots were incubated with antibodies against human c-IAP2 (Santa Cruz Biotech, Santa Cruz, CA, USA), b-actin (Santa Cruz Biotech, Santa Cruz, CA, USA), involucrin (Sigma-Aldrich Corp., St Louis, MO, USA), or HA (Covance Inc., Princeton, NJ, USA).
Transfection and luciferase assay NIH3T3 cells (5 Â 10 4 cells/well) were seeded into 24-well plates the day before transfection. Cells were transfected with total 0.5 mg of DNA including 0.1 mg reporter plasmid, 0.002 mg pRL-SV40 Renilla luciferase reporter gene (Promega, Madison, WI, USA), and 0.4 mg indicated plasmids per well by using Lipofectamine and Plus (Invitrogen, Carlsbad, CA, USA). Transfection was stopped after 3 h by switching to culture medium. Cell extracts were collected 48 h later for luciferase assay with dual luciferase assay kit as instructed (Promega, Madison, WI, USA). The SV40-promoter-controlled Renilla luciferase plasmid (pRL-SV40) was cotransfected as a transfection control. The promoter activities were determined by measuring firefly luminescence intensity against Renilla luminescence intensity.
c-IAP2 siRNA lentiviral vector construction
A short hairpin siRNA primer targeting 1105-1123 nt of c-IAP2 mRNA (GACCATTCAGAAGATGCAA) was synthesized by Sigma Genosys (The Woodlands, TX, USA). The sequence was as follows: 5 0 -TCTGCAGAAAAAGACCATT CAGAAGATGCAATCTCTTGAATTGCATCTTCTGAAT GGTCGGTGTTTCGTCCTTTCCACAA-3 0 . A human U6-RNA pol III promoter was placed before the si c-IAP2 cassette by PCR using M13 primer (5 0 -GGAAACAGCTATGAC CATG-3 0 ) and si c-IAP2 primer with pBS-U6 as template. After digestion with NdeI and PstI, the 130 bp si c-IAP2 expression cassette was inserted to the lentiviral vector pRRLU6shLuc-cppt-PGK-EGFP-SIN with si Luc removed by PstI and NdeI Hui et al., 2004) .
Virus preparation and infection
Vesicular stomatitis virus (VSV)-G-pseudotyped lentiviral vector stocks were produced by calcium phosphate-mediated transient transfection of HEK-293T cells (Yuan et al., 2003) . Briefly, HEK-293T cells were cultured in 10% FCS-Iscove's modified Eagle's medium (JRH Biosciences Inc., Lenexa, KS, USA) at 1.8 Â 10 7 cells in a 175 cm 2 flask. The cells were cotransfected with 12.5 mg vector plasmid, 12.5 mg packaging construct pCMVdR8.2dVpr and 5 mg VSV-G expression plasmid pHCMVG. The viruses were collected from the culture supernatants on days 2 and 3 post-transfection, concentrated 100-fold and stored at À801C. The concentrated virus stocks were titrated by observation of GFP expression in the infected HOK16E6E7 under fluorescence microscope. The infection was performed for 2 h in the presence of 8-10 mg/ml polybrene (Sigma-Aldrich Corp., St Louis, MO, USA). The viral vector contains a GFP expression cassette and an siRNA cassette. The GFP expression can be visualized using fluorescent microscopy as an indication of successful viral infection . Viruses were titrated to ensure that the majority of cells (>95%) were infected. Equivalent amount of si c-IAP2 virus or control si Luc virus were used for the infection. 
TNF-a induction of apoptosis
To induce apoptosis in NHOK infected with HR 0 c-IAP2 and HR 0 GFP, cells were treated with 30 ng/ml recombinant human TNF-a (R&D Systems Inc., Minneapolis, MN, USA), or 30 mg/ml CHX (Sigma-Aldrich Corp., St Louis, MO, USA) or 30 ng/ml TNF-a plus 30 mg/ml CHX for 18-20 h. Cells were then collected for apoptosis assay.
Caspase-3 activity assay
Colorimetric CaspACE Assay System (Promega, Madison, WI, USA) was used to measure the caspase-3 activities. Both floating and adherent cells were harvested and lysed in the lysis buffer. The suspensions were passed through a 28-G needle eight times before spun for 20 min at 41C. The supernatants were transferred to fresh tubes and protein concentration was quantified by Bradford assay (Bio-Rad Laboratory, Hercules, CA, USA). In all, 20-40 mg total proteins were used for each reaction and the assay was performed according to the manufacturer's instruction. The absorbance at 405 nm was measured using a Benchmark Microplate Reader (Bio-Rad Laboratory, Hercules, CA, USA).
In situ TUNEL staining
Apoptosis was also analyzed by monitoring the activity of terminal deoxynucleotidyl transferase using TMR Red In situ Cell Death Detection Kit (Roche Molecular Systems Inc., Branchburg, NJ, USA). DNA breakage induced by apoptosis was detected by labeling cells with fluorescein-conjugated dUTP. Cells grown on coverslips were infected with viruses. After 2-3 days, cells were fixed in 4% paraformaldehyde, permeabilized with PBS containing 0.1% Triton X-100 and 0.1% sodium citrate, and incubated with 50 ml of TUNEL enzyme mixture. After 1 h incubation at 371C, coverslips were rinsed in PBS, and cells were counterstained with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI, Sigma-Aldrich Corp. St Louis, MO, USA) at 1 mg/ml for 12 min. The red fluorescein and DAPI signals were detected using a LEICA DMLB fluorescent microscope equipped with digital camera. The TUNEL-positive cells were counted and the percentage of apoptotic cells was calculated.
Statistical analysis
Luciferase assays, caspase-3 assays and TUNEL assays were performed in triplicate and each experiment was repeated at least three times. The densitometry for Western blot and RT-PCR was conducted using NIH image 1.61 (http://rsb.info. nih.gov/nih-image). The results were normalized against controls. All data are expressed as the mean7s.d. for all of the determinations.
